Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Allergan, Inc.    AGN   US0184901025

ALLERGAN, INC. (AGN)

24
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

Allergan, Inc. : Allergan : Studies Show Botox Treats Overactive Bladder

03/28/2012 | 09:54am US/Eastern
Recommend:
0

Allergan Inc. (AGN) filed applications with U.S. and European regulators for approval to sell Botox as a treatment for overactive bladder as two Phase III clinical trials showed the injectible neurotoxin significantly reduced urinary incontinence when compared with a placebo.

Botox is approved for both cosmetic use, such as fighting wrinkles, and for various medical issues, including urinary incontinence in patients with neurologic conditions such as spinal-cord injury and multiple sclerosis.

Allergan on Wednesday said Botox met the primary endpoints of significantly reducing urinary incontinence, or bladder leakage, episodes in patients who have an inadequate response to or are intolerant of an anticholinergic medication.

Based on the results, Allergan has submitted a supplemental biologics license application with the U.S. Food and Drug Administration and an application with European Regulatory authorities to approve the use of Botox by adult patients not managed by an anticholinergic treatment.

The drug maker has been expanding its pipeline of late, such as buying Vicept Therapeutics Inc., the developer of a cream to treat rosacea, and striking a deal with Map Pharmaceuticals Inc. (MAPP) to jointly promote Map's experimental migraine treatment Levadex.

Allergan reported last month its fourth-quarter earnings rose 6.3% as higher specialty pharmaceuticals sales contributed to a 7.1% revenue jump.

-By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com

Recommend :
0
React to this article
Latest news on ALLERGAN, INC.
54m ago ALLERGAN : Valeant to replace three board members; Allergan adopts poison pill d..
5h ago ALLERGAN : Entry into a Material Definitive Agreement, Material Modification to ..
5h agoDJACKMAN : Poison Pill Is Way for Allegan to Explore Alternatives -CNBC
6h ago ALLERGAN : Valeant CEO 'disappointed' in Allergan poison pill: CNBC
10h ago ALLERGAN : S&P 500 tops its longest rally in 2014 in closing
1d ago ALLERGAN : Adopts One-Year Stockholder Rights Plan
1d ago Activist investors see Ackman-Valeant deal as a model to follow
1d ago Novartis, Valeant bids herald new deal-making era for pharma
1d agoDJALLERGAN PURSUER VALEANT : A Drug Maker With Little Patience for Science
1d agoDJMARKET SNAPSHOT : U.S. Stocks Gain; S&P 500 Extends Streak To Six
Advertisement
Chart
Duration : Period :
Allergan, Inc. Technical Analysis Chart | AGN | US0184901025 | 4-Traders
Income Statement Evolution
Allergan, Inc. : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF